Related references
Note: Only part of the references are listed.NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults
Jessica Mozersky et al.
JAMA NEUROLOGY (2018)
Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context
Gwendolien Vanderschaeghe et al.
NEUROETHICS (2017)
Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context
Gwendolien Vanderschaeghe et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit
Jose L. Molinuevo et al.
ALZHEIMERS & DEMENTIA (2016)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Bruno Dubois et al.
ALZHEIMERS & DEMENTIA (2016)
Patient Requests for Off-Label Bioprediction of Dementia
Matthew L. Baum
CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS (2016)
Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimer's Disease: Opening the Conversation to Prepare Ethical Responses
Eric Racine et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium
Charisse Somers et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review
S. A. S. A. Bemelmans et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges
Bruno Dubois et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Reviewing Literature in Bioethics Research: Increasing Rigour in Non-Systematic Reviews
Rosalind McDougall
BIOETHICS (2015)
Should we screen for cognitive decline and dementia?
Laura Calza et al.
MATURITAS (2015)
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials
Scott Y. H. Kim et al.
NEUROLOGY (2015)
The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment
Rebecca Johnson et al.
SOCIAL SCIENCE & MEDICINE (2015)
Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older Adults
Tara T. Lineweaver et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues
Antoine Leuzy et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction
Silke Schicktanz et al.
FRONTIERS IN HUMAN NEUROSCIENCE (2014)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer's disease: how and what to tell. A kickstart to an ethical discussion
Corinna Porteri et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Keith A. Johnson et al.
ALZHEIMERS & DEMENTIA (2013)
Disclosure of amyloid imaging results to research participants: Has the time come?
Jennifer H. Lingler et al.
ALZHEIMERS & DEMENTIA (2013)
OPINION Preclinical Alzheimer disease-the challenges ahead
Reisa A. Sperling et al.
NATURE REVIEWS NEUROLOGY (2013)
Applying the IWG Research Criteria in Clinical Practice Feasibility and Ethical Issues
Jose L. Molinuevo et al.
MEDICAL CLINICS OF NORTH AMERICA (2013)
Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues
S. Gauthier et al.
PROGRESS IN NEUROBIOLOGY (2013)
MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study
Edo Richard et al.
BMJ OPEN (2013)
Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis
David G. Le Couteur et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Identification of Potential or Preclinical Cognitive Impairment and the Implications of Sophisticated Screening with Biomarkers and Cognitive Testing: Does It Really Matter?
Michael Gordon
BIOMED RESEARCH INTERNATIONAL (2013)
Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D. Grill et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2013)
Making sense of nonsense: experiences of mild cognitive impairment
Renee L. Beard et al.
SOCIOLOGY OF HEALTH & ILLNESS (2013)
Renovating Alzheimer's: Constructive Reflections on the New Clinical and Research Diagnostic Guidelines
Daniel R. George et al.
GERONTOLOGIST (2013)
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues
J. Scott Roberts et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2013)
Ethical issues in Alzheimer's. disease: an overview
Antoine Leuzy et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
The Alzheimer Myth and Biomarker Research in Dementia
Edo Richard et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Diagnostic misconceptions? A closer look at clinical research on Alzheimer's disease
Lara K. Kutschenko
JOURNAL OF MEDICAL ETHICS (2012)
How to write a systematic review of reasons
Daniel Strech et al.
JOURNAL OF MEDICAL ETHICS (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Neuropathologic features associated with Alzheimer disease diagnosis Age matters
L. E. Middleton et al.
NEUROLOGY (2011)
Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease
Jason Karlawish
NEUROLOGY (2011)
Ethical considerations of biomarker use in neurodegenerative diseases-A case study of Alzheimer's disease
David Prvulovic et al.
PROGRESS IN NEUROBIOLOGY (2011)
Timely Diagnosis and Disclosure of Alzheimer Disease Gives Patients Opportunities to Make Choices
G. Richard Holt
SOUTHERN MEDICAL JOURNAL (2011)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Biomarkers, Dementia, and Public Health
C. F. Wright et al.
BIOMARKERS IN BRAIN DISEASE (2009)
Disclosure of APOE Genotype for Risk of Alzheimer's Disease
Robert C. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Early Alzheimer's disease diagnostics: Wait! Wait! Don't tell me!
Meryl Comer
ALZHEIMERS & DEMENTIA (2008)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Ethical, and practical issues in applying functional imaging to the clinical management of Alzheimer's disease
AC Rosen et al.
BRAIN AND COGNITION (2002)
Share Paper
